Differential effects of Paclitaxel on dendritic cell function
/in Dendritic Cells, International Publications /von 2010-03-19 / BMC Immunol. 2010 Mar;11:14Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells
/in Dendritic Cells, International Publications /von 2010-03-18 / Ann. Hematol. 2010 Aug;89(8):795-801Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma
/in Cervical Cancer, Hyperthermia, International Publications /von 2010-03-17 / Cochrane Database Syst Rev 2010 Mar;(3):CD006377Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2010-03-12 / Lung Cancer 2010 Nov;70(2):188-94Building on dendritic cell subsets to improve cancer vaccines
/in Dendritic Cells, International Publications /von 2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-63Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications /von 2010-03-10 / J. Cancer Res. Clin. Oncol. 2010 Nov;136(11):1745-54Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
/in Dendritic Cells, International Publications /von 2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-82New perspectives in cancer virotherapy: bringing the immune system into play
/in International Publications, Newcastle Disease Virus /von 2010-03-01 / Immunotherapy 2010 Mar;2(2):185-99Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia
/in Hyperthermia, International Publications /von 2010-03-01 / Immunol. Res. 2010 Mar;46(1-3):137-54
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution